Contact us for free information or to start a free case review.
After a prominent cardiologist Garret FitzGerald reported a pooled analysis of clinical trial results showed patients taking Pfizer''s Bextra arthritis drug were twice as likely to have a heart attack or stroke as those taking a placebo, Pfizer fired back, defending Bextra. The cardiologist said at a press briefing at the annual meeting of the American Heart Association that an analysis showed Bextra risk to be higher than Merck''s recently recalled arthritis drug Vioxx. Vioxx was recalled after studies showed patients were twice as likely to suffer heart attack and stroke after 18 months of use.
Bextra belongs to the same class of cox-2 inhibitor drugs as Vioxx and Pfizer''s other rival drug Celebrex. Pfizer claims the report drew “unsubstantiated conclusions”. An analyst at World Markets Research thinks Bextra''s future has been shot down after the Bextra findings were made public. FitzGerald said he will submit the results to a medical journal and it will be published. He added he would like the FDA to carefully look at the entire class of drugs, which now only includes Pfizer''s Bextra and Celebrex following the Vioxx recall.
Copyright © 2001 - 2012 Online Lawyer Source
ATTORNEY ADVERTISEMENT—Thank you for your visit. The content published on this website was not written by medical professionals and should not, at any point, be mistaken for medical advice. Furthermore, the information on this site is intended for educational purposes only and should never interfere with a patient/site visitor and his or her healthcare provider. In addition, viewing the content on this website, requesting additional information, or transmitting information through a contact form should never be considered the formation of an attorney-client relationship. The material published on this site is general and may not apply to your specific circumstances. Every case comes with its own set of unique circumstances; past success discussed on this site does not guarantee future performance. Information found on this website should not be used as incentive to act without seeking counsel from a professional. For more information, please read our disclaimer.